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Abstract
The type VI secretion system (T6SS) is a contractile injection apparatus that translocates a
spike loaded with various effectors directly into eukaryotic or prokaryotic target cells. Pseu-
domonas aeruginosa can load either one of its three T6SSs with a variety of toxic bullets
using different but specific modes. The T6SS spike, which punctures the bacterial cell enve-
lope allowing effector transport, consists of a torch-like VgrG trimer on which sits a PAAR
protein sharpening the VgrG tip. VgrG itself sits on the Hcp tube and all elements, packed
into a T6SS sheath, are propelled out of the cell and into target cells. On occasion, effectors
are covalent extensions of VgrG, PAAR or Hcp proteins, which are then coined “evolved”
components as opposed to canonical. Here, we show how various passenger domains
could be fused to the C terminus of a canonical VgrG, VgrG1a from P. aeruginosa, and be
sent into the bacterial culture supernatant. There is no restriction on the passenger type,
although the efficacy may vary greatly, since we used either an unrelated T6SS protein, β-
lactamase, a covalent extension of an “evolved” VgrG, VgrG2b, or a Hcp-dependent T6SS
toxin, Tse2. Our data further highlights an exceptional modularity/flexibility for loading the
T6SS nano-weapon. Refining the parameters to optimize delivery of passenger proteins of
interest would have attractive medical and industrial applications. This may for example
involve engineering the T6SS as a delivery system to shuttle toxins into either bacterial path-
ogens or tumour cells which would be an original approach in the fight against antimicrobial
resistant bacteria or cancer.
Introduction
The type VI secretion system (T6SS) is a versatile nanoweapon, which bacteria like Pseudomo-
nas aeruginosa use to inject effector proteins into target cells. It is proposed that T6SS activity
enables this opportunistic human pathogen to establish a niche in any given polymicrobial
environment or to modulate host cell responses. The expression and activity of the P. aerugi-
nosa T6SS is tightly regulated in vivo and is notably negatively controlled by the RetS sensor
and the RsmA post-transcriptional regulator. As such a retS or rsmA mutant would display
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high level of T6SS activity in laboratory grown conditions [1, 2]. The T6SS consists of a mem-
brane complex anchored to the bacterial cytoplasmic membrane, a cytosolic membrane-
bound baseplate and a contractile sheath growing into the cytosol [3–7]. Inside the sheath,
which is composed of TssB and TssC proteins [8, 9], a tube formed of Hcp hexamers assembles
[10]. On top of the Hcp tube and within the baseplate sits the T6SS spike consisting of a trimer
of VgrG proteins and a conically shaped PAAR protein [11]. Upon sheath contraction, the
Hcp tube together with the VgrG-PAAR spike are propelled out of the cell into the surround-
ing milieu or into the target cell [12]. The VgrG trimer forms a rigid structure due to the inter-
twining of the C-terminal hydrophobic β-sheets [13] with each last β-sheet binding to the
hydrophobic surface of the PAAR protein [11]. This structural feature gives the T6SS spike a
central function in the T6SS: The PAAR protein recruits the cognate VgrG to the baseplate
[14] and the needle-like structure of the VgrG-PAAR spike facilitates the puncturing of target
membrane thus allowing T6SS-related effectors to enter the target cell [11].
Dependent on their delivery mode, T6SS-delivered effector proteins are classified into two
groups: specialised effectors or cargo effectors [15]. A specialised effector contains an N-termi-
nal domain that is a structural component, like VgrG, PAAR or Hcp, that fulfils its role in the
assembly of the T6SS machinery [16]. The C-terminal domain, however, is an extension con-
sisting of an effector domain [17, 18]. As such, a specialized effector with a VgrG support is
called an “evolved” VgrG. In contrast, a cargo effector interacts with a structural component
non-covalently [19].
The effector delivery concept of cargo effectors interacting with Hcp, VgrG or PAAR, was
coined “á la carte” and reflects on the idea that a given T6SS component, in particular a VgrG,
specifically recruits and drives its cognate effector into the target cells [20]. For example, in P.
aeruginosa the three VgrGs, VgrG1a, VgrG1b and VgrG1c were all shown to specifically
deliver their cognate effectors Tse6, Tse7 and Tse5, respectively [20–22]. Furthermore, in
Agrobacterium tumefaciens, P. aeruginosa and enteroaggregative Escherichia coli the cargo
effectors Tde1, PldA/PldB and Tle1, respectively, were shown to specifically interact with the
C-terminal parts of their cognate VgrG proteins leading to their deliveries [19, 23, 24]. Addi-
tionally, some T6SS effectors were identified that require additional proteins, so-called adap-
tors, from the DUF1795, DUF2169 or DUF4123 family for their deliveries [21, 23, 25–27].
Tde1 and Tse6 are such effectors whose deliveries depend on the presence of a cognate Tap1
(DUF4123) or EagT6 (DUF1795) protein, respectively [21, 23, 28]. Furthermore, T6SS effec-
tors were shown to travel within the Hcp ring of the Hcp tube, which was shown for the effec-
tors Tse1, Tse2 and Tse3 from P. aeruginosa [23, 29].
While canonical VgrGs are solely composed of the gp5- and gp27-like domains, named
after the bacteriophage puncturing device [13], and canonical PAARs composed of the PAAR
fold, “evolved” VgrGs and PAARs additionally contain C-terminal extension domains [11,
16]. Two studies reported that the extension domain of a VgrG would be dispensable for VgrG
delivery by substituting the extension with a heterologous effector domain [30, 31]. Further-
more, a recent study showed that the cargo effector PldA is delivered by its cognate VgrG4b
when it is covalently fused to this canonical VgrG protein [24]. These findings led to the gen-
eral assumption that by delivering the VgrG spike into target cells, the covalently fused exten-
sion domain would be co-transported [32]. However, it is not understood yet, whether a VgrG
protein can deliver any extension domain into target cells and whether there are any restric-
tions to this type of delivery mechanism.
Extension domains of evolved VgrG proteins usually harbour enzymatic activities, which in
the cases of P. aeruginosa, Vibrio cholerae, Burkholderia pseudomallei or Aeromonas hydrophila
are involved in host cell subversion to facilitate bacterial uptake [31, 33–35]. So far, two
evolved VgrG with antibacterial extension domains have been characterised, namely VgrG-3
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from V. cholerae [30, 36] and VgrG2b from P. aeruginosa [18]. The C-terminal extension
domain of VgrG-3 was shown to degrade peptidoglycan which is thought to confer a competi-
tive advantage against neighbouring bacteria [36], while the zinc-metallopeptidase domain of
VgrG2b was proposed to interfere with enzymes involved in peptidoglycan remodelling, e.g.
lytic transglycosylase and penicillin-binding proteins [18]. To avoid self-toxicity mediated by
anti-bacterial toxins as well as toxicity of injected effectors from sibling cells, the bacteria need
to produce immunity proteins. Thus, V. cholerae produces a cognate immunity protein TsaB
which tightly interacts with VgrG-3 [36] while P. aeruginosa uses PA0261 as an immunity that
directly interacts with VgrG2b [18].
In the present study, we have tried to broaden the spectrum of VgrG chimera that can be
transported by the T6SS, and tested whether it would be generally possible to manipulate this
system to deliver chosen effector domain. We thus modified the VgrG spike to assess how flex-
ible the delivery mechanisms are. We selected T6SS effectors not naturally using VgrGs for
delivery, T6SS effectors from a different bacterial species, or T6SS-unrelated domains/proteins.
We show that in some cases canonical VgrGs can be modified into “evolved” forms to deliver
different effector domains but it seems clear that this strategy has limitations. Overall, our
work highlights a certain level of modularity of the T6SS spike and provides examples on how
the system can be manipulated to drive secretion of grafted domains from different origins.
Materials and methods
Bacterial strains and growth conditions
Bacterial strains used in this study are described in Table 1. P. aeruginosa strains were grown
in tryptone soy broth (TSB) or LB supplemented with antibiotics where appropriate (spectino-
mycin 2000 μg mL-1) at 37˚C with agitation. E. coli strains were grown in LB broth supple-
mented with antibiotics where appropriate (streptomycin 50 μg mL-1, kanamycin 50 μg mL-1).
DNA manipulation
DNA purification was performed using PureLink Genomic DNA minikit (Life Technologies).
Isolation of plasmid DNA was carried out using the QIAprep spin miniprep kit (Qiagen).
Restriction endonucleases were used according to the manufacturer’s specifications (New
England Biolabs or Roche). Oligonucleotides used are listed in Table 2 and were purchased
from Sigma, United Kingdom. The genes or DNA fragments used for the construction of
mutator plasmids and deletion mutants were amplified with KOD Hot Start DNA Polymerase
(Novagen) as described by the manufacturer with the inclusion of 0.5 M betaine (Sigma). Col-
ony PCR was performed with Taq polymerase (New England Biolabs). DNA sequencing was
performed by GATC Biotech.
Construction of P. aeruginosa mutants
P. aeruginosa deletion mutants were constructed as described previously [42, 43] using the sui-
cide plasmid pKNG101 [40, 44]. Briefly, to create PAO1Δgene-of-interest (GOI), 500-bp DNA
fragments of the 5’ (up) and 3’ (dn) ends of the target gene were obtained by PCR using PAO1
chromosomal DNA as a template with two pairs of oligonucleotides (upF/upR and dnF/dnR)
(Table 2). To create chimeric genes (S1 Fig), splicing by overlap extension PCRs was per-
formed and initiated by three single PCR fragments. Gene fragments containing approxi-
mately 500 bp upstream and downstream of the splice junction were amplified using the
overlapping primers upR and dnF as well as an upstream (exF) and downstream (exR) primer
from the P. aeruginosa genome. A third gene fragment containing the chimera of interest was
VgrG shuttles
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generated using primers upF and dnR that are overlapping with upR and dnF, respectively.
Subsequently, two overlap extension PCR steps were undertaken, employing an equimolar
ratio of the upstream and downstream fragments as the DNA template. The gene fragments
were cloned into pCR-BluntII-TOPO (Invitrogen), their sequences confirmed and sub-cloned
into pKNG101 suicide vector (Table 3). The pKNG-derivatives were maintained in E. coli
strain CC118λpir and mobilized into P. aeruginosa PAK using E. coli 1047 carrying the conju-
gative plasmid pRK2013 [41]. Clones, in which double recombination events occurred, result-
ing in the deletion of GOI or fusion to GOI, were isolated using counterselection on sucrose
plates as previously described [42]. Gene deletion or fusion was verified by PCR using external
primers and western blot analysis where appropriate.
Table 1. Bacterial strains used in this study.
Strain Characteristics Source
P. aeruginosa
PAKΔretS Wild type P. aeruginosa PAK strain with a deletion in retS (PA4856) Lab collection
PAKΔretSΔvgrG1b PAKΔretS with a deletion in vgrG1b (PA0095) [37]
PAKΔretSΔvgrG1b Δtsei2 PAKΔretS with deletions in vgrG1b (PA0095) and tse2- tsi2 (PA2702-PA2703) This study
PAKΔretSΔvgrG1b Δtsei2::lacZ PAKΔretS with deletions in vgrG1b (PA0095) and tse2-tsi2 (PA2702-PA2703), chromosomal insertion of
lacZ at att site
This study
PAKΔretSΔvgrG1b Δtsei2ΔtssB1 PAKΔretS with deletions in vgrG1b (PA0095), tssB1 (PA0083), tse2-tsi2 (PA2702-PA2703) This study
PAKΔretSΔvgrG1b Δtsei2::vgrG1a-tse2tsi2 PAKΔretS with deletions in vgrG1b (PA0095) and tse2-tsi2 (PA2702-PA2703), insertion of gene portion




PAKΔretS with deletions in vgrG1b (PA0095), tssB1 (PA0083), tse2-tsi2 (PA2702-PA2703), insertion of
gene portion for tse2 and tsi2 before vgrG1a (PA0091) STOP codon
This study





PAKΔretS with deletions in vgrG1b (PA0095) and tse2-tsi2 (PA2702-PA2703), insertion of gene portion




PAKΔretS with deletions in vgrG1b (PA0095), tssB1 (PA0083), tse2-tsi2 (PA2702-PA2703), insertion of
gene portion for tse2 and tsi2 before vgrG1a (PA0091) STOP codon, point mutation (S31Q) in hcp1
(PA0085)
This study
PAKΔretS::vgrG1a-blaTEM-1 PAKΔretS with an insertion of blaTEM-1 before vgrG1a (PA0091) STOP codon This study
PAKΔretS::vgrG1a-vgrG2b-CT PAKΔretS with an insertion of gene 821 bp of vgrG2b-CT before vgrG1a (PA0091) STOP codon This study
PAKΔretSΔtssB1 PAKΔretS with deletion in tssB1 (PA0083) [38]
PAKΔretSΔtssB1::vgrG1a- blaTEM-1 PAKΔretS with deletion in tssB1 (PA0083) and an insertion of blaTEM-1 before vgrG1a (PA0091) STOP
codon
This study
PAKΔretSΔtssB1::vgrG1a-vgrG2b-CT PAKΔretS with deletions in tssB1 (PA0083) and an insertion of gene 821 bp of vgrG2b-CT before vgrG1a
(PA0091) STOP codon
This study
PAO1ΔrsmA::pldA-blaTEM-1 PAO1 with deletion in rsmA (PA0905) and an insertion of blaTEM-1 before pldA (PA3487) STOP codon [1]
PAO1ΔrsmAΔtssB2 PAO1 with deletion in rsmA (PA0905) and tssB2 (PA1657) This study
PAO1ΔrsmAΔtssB2::vgrG4b-blaTEM-1 PAO1 with deletion in rsmA (PA0905), tssB2 (PA1657) and an insertion of blaTEM-1 before vgrG4b
(PA3486) STOP codon
This study




DH5α F–endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG purB20 φ80dlacZΔM15 Δ(lacZYA-argF)U169,
hsdR17(rK–mK+), λ–
ThermoFisher
Sm10λpir Host strain for Mini-CTX1 replication: thi thr leu tonA lacY supE recA::RP4-2-Tc::Mu (KmR) λpir [39]
CC118λpir Host strain for pKNG101 replication: Δ(ara-leu) araD ΔlacX74 galE galK-phoA20 thi-1 rpsE rpoB argE
(SmR) recA1 Rfr λpir
[40]
1047 Helper strain for conjugation: (KmR), oriColE1 RK2- Mob+ RK2-Tra+ [41]
https://doi.org/10.1371/journal.pone.0228941.t001
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Table 2. Mutagenesis primers used in this study.
Construct Primer name Code Sequence
pKNG101::hcp1S31Q hcp1 S31Q F OAL3072 GCTGGCATGGCAATGGGGCATGTCCC
hcp1 S31Q R OAL3073 GGGACATGCCCCATTGCCATGCCAGCACG
hcp1 exF OAL3076 CAACATCAACCGCTCCTTCAAG
hcp1 exR OAL3077 GCGGTGGAGTAGGTCTGTAC
pKNG101::vgrG1a-shuttles vgrG1a_exF OAL3735 CGAGGAGATCTGGACCGAC
vgrG1a_exR OAL3736 AAGGACATCGATCCTGCCG
pKNG101::vgrG1a-blaTEM-1 vgrG1a-blaTEM-1_upF OAL1347 GCTAGCCACCCAGAAACGCTGGTG
vgrG1a-blaTEM-1_dnR OAL1348 GCTAGCTTACCAATGCTTAATCAGTGAG
pKNG101::vgrG1a-tse2tsi2 vgrG1a-tse2tsi2_upF OAL1351 GCTAGCATGTCCTACGACTACGAGAA
vgrG1a-tse2tsi2_dnR OAL1352 GCTAGCCCGAAGACCATCTGTCGTTT









Table 3. Plasmids used in this study.
Plasmid Characteristics Source
pRK2013 Self-transmissible helper plasmid for three-partner conjugations, KmR [41]
pKNG101 Non-replicative suicide vector to alter P. aeruginosa chromosome. ori6K,
mobRK2, sacB, SmR
Lab collection





pKNG101 suicide plasmid to integrate blaTEM-1 to pldA gene, SmR [1]
pKNG101::vgrG1a-
blaTEM-1
pKNG101 suicide plasmid to integrate blaTEM-1 to vgrG1a gene, SmR This study
pKNG101::vgrG1a-
tse2tsi2
pKNG101 suicide plasmid to integrate tse2-tsi2 to vgrG1a gene, SmR This study
pKNG101::vgrG1a-
vgrG2b-CT
pKNG101 suicide plasmid to integrate vgrG2b-CT to vgrG1a gene, SmR This study
pKNG101::vgrG4b-
blaTEM-1
pKNG101 suicide plasmid to integrate blaTEM-1 to vgrG4b gene, SmR This study
pKNG101 ΔrsmA pKNG101 suicide plasmid to delete rsmA, a master regulator, SmR [1]
pKNG101 Δtse2tsi2 pKNG101 suicide plasmid to tse2-tsi2, an effector-immunity module,
SmR
[20]
pKNG101 ΔtssB1 pKNG101 suicide plasmid to delete tssB1, an essential sheath
component of the H1-T6SS, SmR
[38]
pKNG101 ΔtssB2 pKNG101 suicide plasmid to delete tssB2, an essential sheath
component of the H2-T6SS, SmR
[1]





Subcloning vector for blunt-ended inserts, KmR ThermoFisher
miniCTX::lacZ Mini-CTX1 harbouring the lacZ with a constitutive promoter, TcR [45]
https://doi.org/10.1371/journal.pone.0228941.t003
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Protein secretion assay
Secretion assays were performed similarly as previously described [37]. Bacterial suspension
was diluted from overnight cultures in TSB to OD600 of 0.1 and grown at 37˚C to an OD600 of
4, unless otherwise stated. A bacterial culture sample adjusted to OD600 of 1 was harvested by
centrifugation and served as the whole cell sample. Simultaneously, 13 mL of culture was cen-
trifuged at 4 000 g for 20 min at 4˚C to separate the bacterial cells from culture supernatant.
10 ml of the supernatant was transferred into falcon tubes and centrifuged again; 7 mL of the
uppermost supernatant was transferred into new tubes and centrifuged. To 1.8 mL superna-
tant fraction, we added 200 μl trichloroacetic acid to precipitate proteins overnight at 4˚C.
The protein precipitate was centrifugated at 16 000 g for 30 min at 4˚C and washed with cold
90% (v/v) acetone before further centrifugation. After removing the supernatant, the washed
pellet was air-dried for 30 min and resuspended in 1x Laemmli buffer to an OD600 equivalent
of 10.
Western blot analysis and SDS-PAGE
For SDS-PAGE analysis, cell extracts were loaded onto SDS polyacrylamide gels, migrated and
transferred to a nitrocellulose membrane at 3 mA/cm2. Following transfer, membranes were
incubated overnight in blocking buffer (5% milk powder, 0.1% Tween 20 in Tris-buffered
saline, pH 8.0). Polyclonal antibodies against VgrG1abc were used at a dilution of 1:1000 [37],
against the C-terminal extension domain of VgrG4b (VgrG4bC) at 1:1000, against Hcp1 at
1:1000 [37], against Hcp2 at 1:1000 [46], against Tse3 at 1:500 [37]. Monoclonal antibodies
against the β subunit of RNA polymerase (RpoB, NeoClone) were used at 1:5000. Secondary
antibodies conjugated to horseradish peroxidase were used at a dilution of 1:5000. Western
blots were developed using Super-Signal West Pico Chemiluminescent Substrate (Pierce) and
visualized on a LAS3000 Fuji Imager.
Interbacterial competition assays
Interbacterial competition assays were conducted on solid media due to the contact-dependent
killing of the T6SS. Prey P. aeruginosa strains contained the Mini-CTX-lacZ integrated at the
att site, consequently giving rise to blue colonies on X-gal-containing media. Overnight cul-
tures in TSB were collected by centrifugation at 8 000 g for 3 min before washing twice in 1 ml
sterile PBS and normalised to OD600 of 3.0. The OD600 was measured again for confirmation
and 100 μl of attacker and 20 μl prey strains were mixed. This mixture was centrifuged at 8 000
g for 3 min and 20 μl supernatant was removed to result in a competition mixture ratio of 5:1
of attacker and prey strains. 5 μl of each competition mix was spotted in duplicates onto LB-
agar, the spots well dried and the Petri dish lids were secured using parafilm M (Bemis). Com-
petition plates were inverted and incubated at 37˚C for 5h for H1-T6SS-inducive killing or at
25˚C for 24h for H2-T6SS-inducive killing.
The input competitions were serially diluted to 10−7, plated on selective media for both
attacker and prey (LB agar with 100 μg mL-1 X-gal for blue/white P. aeruginosa prey/attacker
differentiation) and grown overnight at 37˚C to confirm the input ratios. Competition spots
were gathered using 5 μl inoculation loops (VWR) and resuspended in 1 ml PBS. The competi-
tion output mixture was serially diluted to 10−7, plated on selective media and grown overnight
at 37˚C similarly to the input. Both attacker and prey colony forming units were enumerated
on both input and output dilution plates. All competition assays were repeated three times
unless otherwise stated and the mean cfu of survived prey strains obtained from all experi-
ments with the standard deviation was plotted.
VgrG shuttles
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Results
A “canonical” VgrG can drive the secretion of an effector domain from an
“evolved” VgrG
Several VgrG proteins carry C-terminal extension domains with effector functions and are
thus called “evolved” VgrGs [31, 33–35]. In P. aeruginosa PAO1 only one vgrG gene out of ten
found on the genome was identified to encode an evolved VgrG, namely VgrG2b (S2A Fig,
top panel). VgrG2b carries a DUF2345 domain (bright green) as well as an about 260 aa long
C-terminal extension domain (VgrG2b-CT, red underlined) that can be further distinguished
into a transthyretin- (TTR-) like domain (bright green) and an enzymatic Zn-dependent
metallopeptidase domain (red) [18, 33]. It was shown that the VgrG2-CT could have dual and
trans-kingdom activity since it is translocated into HeLa cells and facilitates actin-dependent
internalisation of P. aeruginosa [33] while it can intoxicate bacterial prey cells when delivered
to the periplasm where it impacts peptidoglycan biogenesis and cell division [18].
Since delivery of VgrG2b-CT is dependent on VgrG2b as a vehicle in PAO1, we wanted to
unravel whether a canonical VgrG could be used to deliver VgrG2b-CT and, thus, whether
canonical VgrGs are transformable into “evolved” VgrGs, which has not yet been assessed. As
a vehicle, we chose the canonical P. aeruginosa VgrG1a that has no C-terminal extension
domain (S2A Fig) and whose secretion is significantly elevated in P. aeruginosa PAK carrying
a deletion for the retS gene [37]. Hence, we designed a strategy to fuse VgrG2b-CT covalently
at the C terminus of VgrG1a in PAK by replacing on the genome the STOP codon of vgrG1a
with the gene sequence corresponding to vgrG2b-CT (S2B Fig). This led to the production of a
Fig 1. VgrG1a-VgrG2b-CT is secreted into the supernatant. (A) Schematic of an evolved VgrG. The green torch-like structure corresponds to the gp5-gp27-like
domains, while the red circles depict the toxic C-terminal extension domains. (B) Design of P. aeruginosa PAK mutants in which the STOP codon of vgrG1a (green)
was replaced on the chromosome with the gene sequence encoding VgrG2b-CT (red), while the downstream region of vgrG1a was unaltered. See S2 Fig for more
details. (C) Representative figure of a western blot from a secretion assay using PAKΔretS carrying an active (+) or inactive (-) H1-T6SS. Strains produce native VgrG1a
(-) or the chimeric fusion VgrG1a-VgrG2b-CT (+). Antibodies (from top to bottom) against VgrG2b-CT, VgrG1abc, RpoB and Hcp1 were used as indicated on the
right. Highlighted with red asterisks are the bands corresponding to the chimera VgrG1a-VgrG2b-CT.
https://doi.org/10.1371/journal.pone.0228941.g001
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chimera of VgrG1a carrying the C-terminal “evolved” domain of VgrG2b (VgrG1a-VgrG2b-
CT, Fig 1A and 1B) which was engineered in a parental strain and its isogenic T6SS-inactive
strain deleted for tssB1 [37].
To investigate whether the VgrG1a-VgrG2b-CT chimera is transported into the bacterial
culture supernatant, secretion assays were performed (Fig 1C). Remarkably, the chimeric
VgrG1a-VgrG2b-CT could be detected at approximately 100 kDa when using a specific antibody
directed against VgrG2b-CT (Fig 1C, top panel, lane 3, asterisk). When probed with an antibody
against VgrG1abc (Fig 1C, second panel) it could be seen that the original VgrG1a is no longer
detectable while a shift towards the 100 kDa protein is now clearly visible (Fig 1C, second panel,
asterisk, lane 3), which overall confirms the identity and size of the VgrG1a-VgrG2b-CT chi-
mera. The same band could be detected in the supernatant fractions of T6SS-active strains (Fig
1C, top and second panels, asterisks, lane 7), but not of T6SS-defective strains lacking the sheath
protein TssB (Fig 1C, top and second panels, lane 8). The specificity of the T6SS-dependent
behaviour is also shown by monitoring Hcp1 secretion (Fig 1C, bottom panel) and the absence
of RNA polymerase RpoB in the culture supernatant (Fig 1C, third panel). This led us to the con-
clusion that VgrG1a can be modified to secrete a heterologous effector domain across the bacte-
rial cell envelope in a T6SS-dependent manner, and that canonical proteins do not seem to have
restrictions to bear extra domains at their C termini. Furthermore, it shows, that the extension
domain of VgrG2b, VgrG2b-CT, does not necessarily require VgrG2b as its vehicle for delivery.
The unrelated passenger protein BlaTEM-1 can be delivered via the T6SS
Next, we wanted to assess whether a T6SS-unrelated passenger domain, the β-lactamase Bla-
TEM-1, can be channelled into the T6SS secretion machine of P. aeruginosa. For this, we chose
the two canonical VgrGs, VgrG1a and VgrG4b (S2A Fig), that are associated with the
H1-T6SS [37] and H2-T6SS [1], respectively. While the majority of H1-T6SS research was con-
ducted in PAKΔretS grown at 37˚C [37], the H2-T6SS has been investigated in PAO1ΔrsmA
grown at 25˚C [1], which is why we used these two different strains in these experiments. We
fused the mature BlaTEM-1, lacking its peptide signal, covalently to both VgrGs in a strategy
similar to the one described for the VgrG1a-VgrG2b-CT fusion above (Fig 2, upper panels).
To assess T6SS-dependent secretion, we additionally used an H1-T6SS- inactive strain, which
is deleted for tssB1 [37], and an H2-T6SS mutant deleted for tssB2 [1].
Secretion assays of T6SS-active and T6SS-inactive strains encoding the VgrG1a-BlaTEM-1
(Fig 2A) and the VgrG4b-BlaTEM-1 (Fig 2B) fusions were performed under H1-T6SS and
H2-T6SS-inducing conditions [1, 37], respectively. Using antibodies against VgrG1abc and
VgrG4b we detected the original proteins at 72 kDa and 90 kDa (Fig 2, upper panels, lanes 1),
respectively. The BlaTEM-1 domain adds 28 kDa, leading to the chimeric VgrG-BlaTEM-1 fusions
to appear as larger products of expected molecular weight, marked with orange asterisks (Fig
2A, lane 2, top panel and Fig 2B, lane 3, top panel, respectively), while the two original pro-
teins, VgrG1a and VgrG4b are no longer visible. The VgrG1a-BlaTEM-1 (Fig 2A, lane 6, top
panel) as well as the VgrG4b-BlaTEM-1 (Fig 2B, lane 7, top panel) proteins can be found in the
supernatant fractions of T6SS-active strains (orange asterisks), but not of T6SS-inactive strains
(Fig 2, each lane 8). It is noteworthy, that in both cases, bands corresponding to the original
VgrG1a and VgrG4b, respectively, are observable in the supernatant fractions of T6SS-active
strains (green asterisks in Fig 2A, lane 6, top panel, and Fig 2B, lane 7, top panel, respectively).
As these are not seen in the cell fraction (Fig 2A, lane 2, top panel and Fig 2B, lane 3, top
panel), it is proposed that these bands might result from degradation and proteolytic cleavage
of the BlaTEM-1 domain from the chimera once released extracellularly. Thus, we showed that a
canonical VgrG can secrete a T6SS-unrelated domain when covalently fused.
VgrG shuttles
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Grafting an Hcp-dependent effector on a canonical VgrG
A number of T6SS effectors were proposed to be delivered within the Hcp tube. In P. aerugi-
nosa these are Tse1, Tse2 and Tse3 which are bound within the Hcp1 ring [23, 29]. Tse1 and
Tse2 are thought to fold into small enough proteins to fit the Hcp1 ring cavity, while Tse3
adopts a lengthy structure to plug into the lumen of Hcp1 hexamers [47–50]. For our study,
we chose the Hcp1-dependent effector Tse2, whose stability highly depends on its interactions
with Hcp1 [29]. Thus, we challenged the VgrG shuttle concept by the attempt to deliver an
Hcp-dependent T6SS effector as an extension domain of VgrG and thus uncouple the T6SS
effector from its original Hcp vehicle.
To monitor whether the canonical VgrG1a would be able to deliver Tse2 into the superna-
tant or bacterial preys, we followed the previous grafting strategy and fused tse2 to vgrG1a by
allelic replacement of the vgrG1a STOP codon directly on the chromosome (Fig 3A). To avoid
toxicity against sister cells, the cognate immunity tsi2 was also cloned so that this gene now lies
immediately downstream of the vgrG1a-tse2 allele in the vgrG1a cluster. At the same time, the
native tse2tsi2 (tsei2) locus was deleted (Fig 3A). The VgrG1a-Tse2 chimera has an expected
molecular size of about 91 kDa, which would then be similar to VgrG1b. Because the
VgrG1abc-antibody also recognises VgrG1b [37], the vgrG1a-tse2 chimera was engineered in
mutant strains lacking the vgrG1b gene.
Western blot analysis using an antibody against VgrG1abc shows that only VgrG1a and
VgrG1c are detectable in whole cells of the parental strain (Fig 3B). For strains carrying the
vgrG1a-tse2 fusion, an additional band corresponding to VgrG1a-Tse2 is readily visible (Fig
3B, lane 2, red asterisk), while a band corresponding to the original VgrG1a is still observable
(Fig 3B, lane 2, green asterisk). This suggests that the chimera VgrG1a-Tse2 is expressed, but
likely prone to proteolytic cleavage. VgrG1a-Tse2 is further detectable in the supernatant of
T6SS-active cells (Fig 3B, lane 5, red asterisk) suggesting chimera secretion, while a band corre-
sponding to VgrG1a itself is also detectable in the supernatant fraction (Fig 3B, lane 5, green
asterisk). However, it is not clear whether presence of VgrG1a in the supernatant results from
cleavage of the chimera after secretion or, most likely, whether intracellularly cleaved VgrG1a
is secreted. Importantly, in the supernatant fraction of T6SS-defective strains (Fig 3B, lane 6),
Fig 2. VgrG-BlaTEM-1 fusions can be secreted into the supernatant. Top panels: the gene encoding BlaTEM-1 (orange) was fused to (A) vgrG1a and (B) vgrG4b, while
each downstream region on the chromosome was left unaltered. Bottom panels: representative figures of western blots of secretion assays using (A) PAKΔretS carrying
an active (+) or inactive (-) H1-T6SS and expressing native VgrG1a (-) or the chimeric VgrG1a-BlaTEM-1 (+), or (B) PAO1ΔrsmA carrying an active (+) or inactive (-)
H2-T6SS encoding VgrG4b-BlaTEM-1 (+). Antibodies used (from top to bottom) are against (A) VgrG1abc, RpoB and Hcp1 or (B) VgrG4b
C, RpoB and Hcp2, as
indicated on the right. Highlighted with orange asterisks are bands corresponding to (A) VgrG1a-BlaTEM-1 or (B) VgrG4b-BlaTEM-1, while highlighted with green
asterisks are degradation products corresponding to (A) native VgrG1a or (B) native VgrG4b.
https://doi.org/10.1371/journal.pone.0228941.g002
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which is lacking the essential component TssB1, the bands corresponding to VgrG1a-Tse2,
VgrG1c, VgrG1a and Hcp1 are mostly absent although residual amount is detected. Yet, Tse3,
another Hcp1-dependent effector, was used as an additional control for secretion (Fig 3B, bot-
tom panel, upper band with blue asterisk), and was not detected in the supernatant of a T6SS
inactive strain. Finally, the intracellular control RpoB (Fig 3B, second panel) is not detectable
in the supernatant indicating that cell lysis is unlikely and presence/absence of proteins in the
supernatant is thus T6SS-dependent.
A previous study reporting the interaction between Hcp1 and Tse2 [29] showed how stabil-
ity and delivery of Tse2 is highly dependent on Hcp1 and pinpointed key interaction residues
on the inside of the Hcp1 lumen (Fig 3C). A range of highly conserved residues within the
Hcp1 lumen appeared to be essential for interactions with Tse2 and mutation in each of these
residues confirmed that Tse2 stability and secretion were drastically impaired [29]. In particu-
lar substitution of Serine (S) at position 31 for Glutamine (Q), yielding Hcp1S31Q, resulted in a
huge decrease in the amount of intracellular Tse2 [29] (Fig 3C). Here, we used a similar back-
ground to assess how this residue might impact secretion of the VgrG1a-Tse2 chimera so that
we repeated all above secretion assays including mutants expressing Hcp1S31Q (Fig 3D).
Fig 3. VgrG1a moderately secretes covalently fused Tse2. (A) Design of mutants in which the STOP codon of vgrG1a was replaced on the chromosome with the gene
sequence encoding tse2-tsi2 (red-cyan) while native tse2-tsi2 (PA2702-PA2703) was deleted. (B, D) Representative western blots of secretion assays using
PAKΔretSΔvgrG1bΔtsei2 expressing native VgrG1a (-) or the chimeric fusion VgrG1a-Tse2 (+). Strains in (B) produce an active (+) or inactive (-) H1-T6SS, while
strains in (D) additionally encode native Hcp (-) or mutant HcpS31Q (+). Antibodies used (from top to bottom) are against VgrG1abc, RpoB, Hcp1 and the
Hcp1-dependent effector Tse3 as indicated on the right. Highlighted with red asterisks are bands corresponding to VgrG1a-Tse2, while highlighted with green asterisks
are degradation products likely corresponding to native VgrG1a and blue asterisks correspond to the Tse3 effector. (C) Hcp1 dimer (pdb: 1Y12) in yellow and
highlighted inside the Hcp1 lumen in blue are the native serine (upper panel) or in red the mutated glutamine (bottom panel).
https://doi.org/10.1371/journal.pone.0228941.g003
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Secretion of VgrG1a, VgrG1c, Hcp1 or Tse3 was not affected when cells contain the
hcp1S31Q variant (Fig 3D, lane 5). This is in good agreement with the previous study, in which
it was shown that Tse3 secretion was not affected by the hcp1S31Q variant mutation [29]. In a
context where vgrG1a was replaced with vgrG1a-tse2 (Fig 3D, lane 2), the abundance of the
band corresponding to VgrG1a-Tse2 is higher in a parental background as compared to the
hcp1S31Q mutation (Fig 3D, top panel, compare lanes 2 and 3, red asterisk). This is likely caused
by the fact that Tse2 no longer interacts with Hcp1S31Q leading to destabilisation of the effector
with subsequent degradation. The reduced amount of VgrG1a-Tse2 is also reflected by the
absence of detectable secretion of the full-length chimera (Fig 3D, lane 7, top panel) in contrast
to the parental background (Fig 3D, lane 6, top panel, red asterisk). Yet, in strains containing
the hcp1S31Q mutation (Fig 3D, lane 7, top panel, green asterisk), a rather intense band corre-
sponding to VgrG1a is visible in the supernatant fraction of hcp1S31Q mutants, as compared to
the wild-type background. This suggests that either the secreted chimera is unstable or that the
truncated VgrG1a from the VgrG1a-Tse2 chimera in the cell is efficiently secreted.
Overall, we conclude that the VgrG1a-Tse2 chimera can be partially secreted in a T6SS-
dependent manner but restricted by the chaperoning function of Hcp1 for Tse2. It remains
further elusive whether binding of the Hcp1 component to the chimera and at the tip of the
T6SS is occurring prior and during the secretion process.
Effector domains fused to a canonical VgrG are not efficiently delivered
into target cells
We have shown that BlaTEM-1 can be secreted when fused to VgrG1a and VgrG4b, while Tse2
is not effectively released into the supernatant as a VgrG1a-Tse2 chimera. We further asked
whether these fusions could be delivered into target cells. BlaTEM-1 is a common reporter
enzyme to monitor translocation into eukaryotic cells [51, 52], while Tse2 is a toxin with its
final destination being bacterial prey cells [53]. Hence, it was assessed whether VgrG1a or
VgrG4b could fulfil a role that will drive BlaTEM-1 or Tse2 all the way from the producing bac-
teria into the cytosol of HeLa cells or into bacterial competitors (Fig 4).
The enzymatic activity of BlaTEM-1 is the readout for a cell-based translocation assay as
described previously [55]. As a positive control for the experimental setup, a fusion between
BlaTEM-1 and the T6SS effector PldA was engineered, since it has been shown before that a
PldA-BlaTEM-1 fusion is translocated into infected HeLa cells in a T6SS-dependent manner [52],
which we could confirm here (Fig 4A, lane 1). Our negative controls are either a mutant not
encoding a BlaTEM-1 (Fig 4A, lane 5) or a non-deliverable VgrG1a-BlaTEM-1 produced in a
T6SS-defective mutant (Fig 4A, lane 4). The test strains that express either VgrG4b-BlaTEM-1
(Fig 4A, lane 2) or VgrG1a-BlaTEM-1 (Fig 4A, lane 3) display a significant difference as compared
to the positive control (� p< 0.5; ��� p< 0.001) but no significance as compared to the negative
controls, suggesting that no BlaTEM-1 translocation occurred. Results obtained here reflect that
the fusion proteins were unable to puncture the eukaryotic cell membrane, or that the VgrG
chimera falls out of the device before it could be engaged in such process. This could be a rea-
sonable hypothesis for VgrG1a-BlaTEM-1, which is entirely artificial. However, in the case of
VgrG4b-BlaTEM-1, it could have been expected to work since VgrG4b is the cognate VgrG for
PldA, which we showed here is efficiently delivered as a PldA-BlaTEM-1 chimera (Fig 4A) [1, 24].
Next, we performed a bacterial competition assay [56] to evaluate whether Tse2 can reach
its target in a T6SS-dependent manner but irrespective of its delivery mode. This will also dem-
onstrate that a canonical VgrG, such as VgrG1a, is not only able to puncture the cell envelope
of the producing cell but can also puncture bacterial prey cells. For effective intra-bacterial kill-
ing assays, P. aeruginosa prey cells were constructed that lack vgrG1b and were sensitive to
VgrG shuttles
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Tse2 by lacking the effector gene tse2 and its cognate immunity gene tsi2. The attacking strains
expressed either VgrG1a or the VgrG1a-Tse2 fusion (Fig 4B). When the parental strain
(PAKΔretSΔvgrG1b, Fig 4B, lane2) is the attacker, it effectively outcompeted the prey strain,
however a strain expressing VgrG1a-Tse2 did not (Fig 4B, lane 4). This suggests that VgrG1a-
Tse2, even though moderately released into the supernatant, cannot be driven as a chimera all
the way into prey cells. Furthermore, strains that additionally harbour the hcpS31Q mutation do
not have a competitive advantage towards the prey cell (Fig 4B, lane 6), corroborating our
results from the secretion assay. These results imply that neither VgrG4b nor VgrG1a can
deliver their covalently fused extension domains into target cells.
Discussion
Using bacterial protein secretion systems as a shuttle to deliver proteins in a targeted manner
has been considered for many years. In particular, it was previously attempted to use the type
III secretion system to deliver specific molecules into an appropriate environment. One exam-
ple is the T3SS-dependent delivery of angiogenesis inhibitors by Salmonella, which proved sig-
nificant anti-tumoral activity on mice colon carcinoma [57]. As such, bacterial secretion
devices able to deliver proteins directly into the cytosol of human cells are considered the shut-
tles of choice when developing targeted medicine strategies [58]. The T6SS also injects toxins
into bacterial preys and might thus be considered as a strategy to counteract pathogen infec-
tions if used by commensal bacteria present in an infected host [59]. Here, we developed this
idea of the T6SS as a shuttle. The prerequisite to any future potential biotechnological applica-
tions, which is not the purpose of the present study, is to manipulate the T6SS and assess
whether secretion/delivery of chosen effectors can be eased when these are connected to the
VgrG tip. We could show that a canonical VgrG can be modified so that it is able to deliver an
effector domain across the bacterial membrane.
Previous studies investigated secretion and translocation of evolved VgrGs (S3A Fig). Some
studies used the β-lactamase as a reporter to follow the fate of VgrG chimera by monitoring
translocation into eukaryotic cells [31, 35, 51]. In these cases, the β-lactamase domain was
either used to extend an evolved VgrG or to substitute the extension domain thus mainly prov-
ing that the effector domain is not essential for VgrG delivery [31] (S1 Table). Another study
previously showed that the covalent fusion of PldA to its cognate VgrG4b resulted in its secre-
tion and delivery into target cells [24]. In the current study, we were able to corroborate these
findings but expanded this knowledge to the concept that it is possible to extend a canonical
VgrG with BlaTEM-1 or another effector domain and thus to create an artificial evolved VgrG.
In the attempt to modify the secretion route of Tse2, we corroborated previous evidence
that Tse2 starkly requires Hcp1 for stability and for connecting it to the T6SS tip complex (Fig
5A and 5B) [29]. From our results, we could propose that Tse2, even when fused to another
vehicle, like VgrG1a, still interacts with Hcp1. This may explain the low level of chimera
Fig 4. VgrG1a cannot deliver covalently fused effector domains into target cells. (A) HeLa cells were infected with P. aeruginosa strains for 3 h, washed
and incubated with CCF2/AM substrate for 90 min. After extensive washing, emission of cells was measured. The translocation rate (emission of blue
fluorescence/emission of green fluorescence) is expressed for each sample in relation to the emission ratio of uninfected cells [54]. A high translocation
rate was observed for the positive control PldA-BlaTEM-1 (::pldAB, lane 1), but not for the negative controls VgrG1a-BlaTEM-1 (::vgrG1aB) from T6SS-
deficient strains (lane 4) or when no chimera is present PAKΔretS (+, lane 5).The positive control PldA-BlaTEM-1 (::pldAB, lane 1) was translocated, but
not the negative control VgrG1a-BlaTEM-1 (::vgrG1aB) from T6SS-deficient strains (lane 4). An ordinary one-Way ANOVA analysis with Dunnett’s
multiple comparisons test of three independent experiments was conducted on the data set obtained from the positive control with ��� p<0.001. (B)
Bacterial competition represented by plot from four independent experiments of recovered cfu of the prey strain PAKΔretSΔvgrG1bΔtsei2::lacZ after
contact with the attacker strain that encodes Tse2-Tsi2 (+), Hcp1S31Q (+) or the chimera VgrG1a-Tse2 (+), as indicated. Spots were incubated for 5 h at
37˚C in a 5:1 ratio. One-Way ANOVA analysis with Dunnett’s multiple comparisons test was conducted on data set obtained from recovered prey on
their own with �� p<0.01.
https://doi.org/10.1371/journal.pone.0228941.g004
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secretion observed, likely due to steric hindrance when engaging into the secretion system and
notably the T6SS baseplate and membrane complex. (Fig 5C). However, it seems that abolish-
ing this interaction by mutating a conserved residue within the Hcp1 lumen still resulted in
degradation of the chimera (Fig 5D). This fully supports the concept of Hcp1 being a chaper-
one and receptor for Tse2 [29] (S3B Fig) even when the latter is fused to a VgrG protein.
T6SS effectors were identified that connect to the T6SS tip via binding to C-terminal resi-
dues of a VgrG protein (S3C Fig) or to a transthyretin-like (TTR) domain within the C-termi-
nus of a VgrG (S3D Fig). In many cases, binding to the last amino acids of a VgrG protein is
mediated by a chaperone from the DUF4123 family, as for Tde1 from A. tumefaciens [23] or
TseL in V. cholerae [25, 26]. Recent studies showed that Tle1 in E. coli as well as PldA and PldB
in P. aeruginosa specifically interact with the C-terminal TTR-like domains of the respective
upstream encoded VgrG1Eco, VgrG4bPaer and VgrG5Paer [19, 24]. Flaugnatti et al. also demon-
strated that delivery of Tle1Eco solely depends on the TTR-like domain of VgrG1Eco [19].
Another recent study showed that by swapping the TTR-like domains between VgrG4bPaer
and VgrG5Paer, the specificity of the VgrG for their effectors would also be swapped [24].
Fig 5. Model of interference of interactions between the Hcp1 ring and Tse2 as part of a VgrG1a-Tse2 shuttle. A: In the parental strain Tse2 (red) interacts with the
key conserved residues (Q31 amongst others) within the lumen of Hcp1 (brown) leading to stabilisation and subsequent delivery of Tse2. A trimer of VgrG proteins
(green, PDB: 4mtk) sits on top of the Hcp1 tube. B: One key residue within the Hcp1 lumen mediating interactions with Tse2 is mutated (S31Q). This prevents
incorporation of Tse2 into the Hcp1 tube and renders it prone for proteolytic degradation (indicated by blue bolt). C: Tse2 is covalently fused to the canonical VgrG1a.
Hcp1 molecules are recruited to the tip due to their high affinity for Tse2 leading to a bulky tip complex and blockage of the T6SS. D: One key residue is mutated within
the Hcp1 lumen (S31Q) thus abolishing interactions with Tse2. This leads to destabilisation of Tse2 as C-terminal extension of VgrG1a, so that cleavage of Tse2 occurs
and most likely degradation of the effector. WT VgrG1a is accumulated and can be incorporated into the T6SS complex and thus reaches the supernatant. This model is
based on the data obtained in this current study and in the study by Silverman et. al [29].
https://doi.org/10.1371/journal.pone.0228941.g005
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In addition to loading an effector directly onto a VgrG protein, effectors can also be con-
nected to PAAR proteins (S3E Fig). PAAR domains can be part of an effector and thus help
loading the extended effector domain directly onto the spike complex [11]. The involvement of
additional proteins was also shown, like DUF1795, namely Eag proteins [21, 27, 28, 60, 61] and
DUF2169 proteins [23]. The Eag proteins EagR1 and EagR2 from S. marcescens were observed
to specifically bind and likely stabilise the N-terminal regions of their cognate effectors Rhs1
and Rhs2, respectively [62] (S3E Fig). In contrast, the involvement of a DUF2169 protein in
effector delivery was so far only shown for Tde2 delivery in A. tumefaciens [23]. However, the
molecular function of a DUF2169 protein and its detailed role in mediating effector delivery
remains elusive. Additionally, PAAR effectors were characterised that additionally contain a
large Rhs core [20]. The structure of such Rhs core domain was solved and showed that it forms
a shell-like shape enclosing the C-terminal effector domain [63]. Recently, it was also suggested
that the C-terminal effector domain might be cleaved from the Rhs core before translocation
[64]. However, the accommodation of this large protein around the T6SS tip complex and the
molecular mechanisms of effector translocation remain to be further characterized.
The fact that effectors can be attached to the T6SS via different mechanisms highlights its
versatility and suggested that it could be a useful potential vehicle to deliver a range of effectors
into bacterial preys. However, details of the molecular delivery mechanisms are still unclear
for many T6SS effectors and the diversity in branching effectors to the machine makes it also
very complex in deciding what the best configuration for a vehicle/passenger could be. Here,
we made use of the simplest known delivery mechanism by fusing effector domains to the
structural component VgrG. Although we showed that this configuration is sufficient to
secrete the effector domain outside of the producing cell, this occurs with variable efficacy
while the delivery into a target cell is not guaranteed since none of our chimera could be effi-
ciently injected into the intended target cell. It is not clear why this is the case, and one would
need to try using other canonical VgrGs to assess whether it is a general problem or whether it
is specific to VgrG1a. One possibility is that modifying the tip of the VgrG protein might desta-
bilize the binding of the cognate PAAR protein [11]. Under such configuration, the PAAR
association with the VgrG chimera might be preserved while the complex is embedded within
the TssBC sheath/T6SS baseplate or the TssJLM membrane complex, and this would be suffi-
cient to perforate the membrane of the producing cell. Yet, the VgrG/PAAR association might
not be strong enough to allow penetration of the chimera into target cells once it is expelled
from the attacker cell. In light of our data, the biotechnological applications of VgrG-shuttling
are likely possible. As it stands, developing this type of approaches would require a better
molecular understanding of the organization around the VgrG tip, so that further engineering
may make effective the delivery into target cells.
Supporting information
S1 Fig. Strategy to construct chimeric P. aeruginosa mutants. A: Three DNA fragments
were produced with primers exF and upR; upF and dnR; dnF and exR with upR and upF and
dnR and dnF containing overlapping sequences. upF and dnR produce the fragment (blue)
that would be introduced into the genome (yellow). B: Two consecutive overlap PCRs, ulti-
mately using exF and exR, produce a fragment that was cloned into the suicide plasmid
pKNG101 and introduced into the genome. After a double recombination event, presence of
the chimeric gene was verified by PCR using exF and exR.
(TIF)
S2 Fig. Design of VgrG-shuttles used in this study. A: Protein domains of the here used
VgrG2b (PA0262), VgrG1a (PAK00309) and VgrG4b (PA3489). The N-terminal part of all
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three VgrGs are the gp5/gp27-like domains (greens) spanning the first approximately 610 aa.
In VgrG2b, this region is followed by a DUF2345 and a transthyretin-like domain (grey-
green) [33]. The C-terminal 170 aa comprise of the metallopeptidase domain (red). VgrG4b,
as well, harbours a TTR-like domain [19]. B: Genetic environments of the vgrG2b and vgrG1a
genes in P. aeruginosa PAO1 and PAK. The vgrG2b gene (green-red) in P. aeruginosa PAO1 is
followed by the gene PA0261 (cyan). In PAK, downstream of vgrG1a (green), tse6 (dark red)
and the immunity tsi6 (cyan) are located.
(TIF)
S3 Fig. Effector proteins can be connected to the T6SS tip via different mechanisms. (A)
An effector domain is part of an evolved VgrG (green, model PDB: 4mtk) and is thus part of
the VgrG spike tip. (B) T6SS effectors (red) are bound and stabilised by Hcp-hexamers (grey)
and recruited towards the T6SS tip via assembly of the Hcp-tube. (C) An effector directly
interacts with its cognate Tap protein (magenta) which stabilises it and recruits the effector to
the T6SS tip. (D) An effector directly interacts with the C-terminal TTR-like domain (green
arc) of a VgrG that both connects it to the T6SS tip and stabilises the effector protein. (E) An
effector contains an N-terminal PAAR domain (purple) that associates at the VgrG trimer and
the effector hydrophobic transmembrane domains are chaperones in the cytosol by specific
Eag proteins (orange). In all cases, by propelling out the Hcp tube with the VgrG spike on top,
the effector proteins or domains are translocated across the bacterial cell membranes.
(TIF)
S1 Information File. RAW data of western blot images. The RAW images are present in the
file in the order they occur in the document. The lanes are labelled with the strain names from
which the samples derive. The antibody against which was blotted, is noted. Lanes that are not
shown in the final document are marked.
(PDF)
S1 Table. Overview of known evolved VgrGs from the literature and from the current
study. Names of the VgrGs are adapted from the literature with superscripted abbreviations
corresponding to the organism the VgrG is derived from (Paer—P. aeruginosa; Vcho–V. cho-
lerae; Ahyd–A. hydrophila; Bpse–B. pseudomallei; Ftul–Francisella tularensis). If no organism is
mentioned, its source is P. aeruginosa. Artificially chimeric VgrGs with fused effector domains
are highlighted with a grey background. The table lists the enzymatic activities of the extension
domains and their size. It further highlights whether the evolved VgrG was found secreted in
the supernatant and whether translocation in either eukaryotic or prokaryotic cells was shown.
(DOCX)
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